Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of tables on pelareorep trials, cash-runway projections, and licensing clauses can make a single Oncolytics Biotech annual report 10-K feel impenetrable. If you have ever searched for one line that explains when the next financing might dilute shareholders, you understand the problem. Stock Titan’s AI turns that 300-page document into a concise briefing—Oncolytics Biotech 10-K simplified—so you spend minutes, not hours, finding answers.
The platform monitors EDGAR around the clock, posting Oncolytics Biotech Form 4 insider transactions real-time alongside a clear narrative of why each trade matters. You’ll also see every Oncolytics Biotech quarterly earnings report 10-Q filing, complete with cash-burn trends and trial-cost breakdowns. Want alerts the moment an 8-K appears? Our engine publishes Oncolytics Biotech 8-K material events explained before most investors finish typing the ticker.
Below, you can quickly jump to what professionals ask for most:
- Pelareorep R&D spending and phase-data timelines in the latest Oncolytics Biotech earnings report filing analysis
- Board pay details inside the Oncolytics Biotech proxy statement executive compensation
- Cash-raise clauses hidden in shelf-registration exhibits, surfaced by our AI summaries
- Oncolytics Biotech insider trading Form 4 transactions that reveal management’s conviction
Whether you’re monitoring dilution risk or validating upcoming study catalysts, understanding Oncolytics Biotech SEC documents with AI means the numbers, risks, and opportunities are already highlighted. Explore every filing type—10-K, 10-Q, 8-K, S-3, and more—updated the second they post. Complex biotechnology disclosures have finally met their match.
Oncolytics Biotech Inc. established an at-the-market program to sell up to $50.0 million of common shares through BTIG, LLC, which may be sold from time to time under a shelf registration on Form F-3 and an accompanying prospectus supplement. The company will pay a 3.0% commission on gross proceeds, and either party may terminate the agreement on 10 days’ notice.
Any net proceeds will be used to fund clinical development of pelareorep, related R&D, operating costs, working capital and general corporate purposes. The company states that no shares may be offered or sold in Canada.
Separately, the company filed a Form F-4 for a planned domestication from Alberta, Canada to Nevada, intended to be effective when it ceases to be a foreign private issuer on January 1, 2026 or as soon as practicable thereafter. The company cites perceived benefits of Nevada’s corporate law but notes there is no assurance the domestication will occur on the expected timeline or deliver the anticipated benefits.
Oncolytics Biotech Inc. filed a Form F-4 and sent a combined management information circular and prospectus seeking shareholder approvals to change its jurisdiction in two steps: first a continuance from Alberta to British Columbia, then a domestication to Nevada, and to adopt the 2025 Incentive Award Plan. Each step is subject to the required shareholder vote and the Board’s discretion to proceed.
If completed, each outstanding common share will continue as one share through the Continuance and become one share of Oncolytics Nevada common stock without any surrender or exchange. The company’s shares will continue to trade on Nasdaq under ONCY. Dissent rights are available under Alberta and British Columbia law as described, and the filing includes risk factors and tax considerations related to the redomiciliation.
Oncolytics Biotech Inc. (ONCY) launched an at-the-market offering of up to $50,000,000 in common shares through BTIG, LLC, which may act as sales agent or principal. Sales may be made from time to time in transactions deemed an “at the market offering” under Rule 415.
The Agent will receive a 3.0% commission on gross proceeds. On October 16, 2025, ONCY last traded at $1.17 per share on Nasdaq. The company intends to use net proceeds to fund clinical development of pelareorep, associated R&D, operating costs, working capital and general corporate purposes.
As context, common shares outstanding were 97,407,903 as of June 30, 2025. Assuming sales at $1.17, the company illustrates up to 42,735,042 shares sold, with up to 140,142,945 shares outstanding immediately after the offering. Under that assumption, the filing shows an immediate dilution of $0.79 per share to new investors at the assumed price.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
